Eli Lilly in big reshuffle: Sets up new units for neuroscience and immunology

The US-based pharmaceutical company has kicked off a big management reshuffle after a top-level decision ordered independent units for neuroscience and immunology, with the latter handling a potential launch of Alzheimer's drug donanemab.
Photo: Mike Blake/REUTERS / X00030
Photo: Mike Blake/REUTERS / X00030

Oncology and the larger Bio-Medicines division will be hit particularly hard now that Eli Lilly initiates a series of larger organizational changes.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading